{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:47Z","timestamp":1792511927915,"version":"4.5.0"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Seasonal influenza remains a major global public health challenge despite decades of vaccine development, underscoring the need for more effective and adaptable immunization strategies. The recently approved mRNA-1010 vaccine represents a promising advance by applying messenger RNA technology to a pathogen characterized by continuous antigenic drift. Recent Phase 3 clinical trials conducted in support of regulatory review have demonstrated robust immunogenicity and superior protective efficacy against seasonal influenza compared with standard influenza vaccines in adults aged 50 years and older. However, increased reactogenicity, particularly among younger adults, together with the need for continued post-marketing safety surveillance, highlights the balance between enhanced immune responses and tolerability. Beyond seasonal influenza, mRNA-1010 provides a foundation for next-generation respiratory vaccines, including combination formulations targeting influenza, SARS-CoV-2, and respiratory syncytial virus (RSV), while illustrating the broader potential of mRNA vaccine technology. At the same time, challenges related to manufacturing scalability, cost, cold-chain requirements, and global accessibility remain important considerations for widespread implementation. This perspective examines whether mRNA-1010 represents an incremental advance in influenza vaccination or a potential transformative milestone in respiratory immunization, while considering the continuing roles of alternative vaccine platforms in achieving optimal effectiveness, safety, and equitable global access.<\/jats:p>","DOI":"10.3390\/vaccines14080709","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:08:41Z","timestamp":1787040521000},"page":"709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["mRNA-1010 and the Future of Seasonal Influenza Prevention: Towards Next-Generation Respiratory Vaccination"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2697-0654","authenticated-orcid":false,"given":"Antonios-Periklis","family":"Panagiotopoulos","sequence":"first","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1978-5864","authenticated-orcid":false,"given":"Deny","family":"Tsakri","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Ranellou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"},{"name":"1st Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos General Hospital, 10676 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-9198","authenticated-orcid":false,"given":"Cleo","family":"Anastassopoulou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-4715","authenticated-orcid":false,"given":"Athanasios","family":"Tsakris","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2521324","DOI":"10.1001\/jamanetworkopen.2025.21324","article-title":"Estimated Burden of Influenza and Direct and Indirect Benefits of Influenza Vaccination","volume":"8","author":"Krauland","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_2","unstructured":"CDC (2026, July 04). 2024\u20132025 Influenza Season Summary: Severity, Disease Burden, and Burden Prevented, Available online: https:\/\/www.cdc.gov\/flu-burden\/php\/data-vis-vac\/2024-2025-prevented.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2618581","DOI":"10.1001\/jamanetworkopen.2026.18581","article-title":"Influenza Activity and Estimated Vaccine Effectiveness During the 2025\u20132026 Influenza Season","volume":"9","author":"Budd","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s40121-026-01384-7","article-title":"Clinical and Economic Inpatient Burden of Influenza and Influenza-Like Illness in Germany 2019\u20132025: Analysis of Nationwide Hospital Data","volume":"15","author":"Meyer","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40265-024-02083-8","article-title":"Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine","volume":"84","author":"Cowling","year":"2024","journal-title":"Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Chai, S., Ye, C., Fan, C., and Jiang, H. (2025). Brief Comparison of Novel Influenza Vaccine Design Strategies. Vaccines, 13.","DOI":"10.3390\/vaccines13111164"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2336357","DOI":"10.1080\/21645515.2024.2336357","article-title":"Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines","volume":"20","author":"Russell","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(26)00512-X","article-title":"Safety and efficacy of mRNA vaccines: A mechanistic and public health perspective","volume":"408","author":"Blakney","year":"2026","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa2516491","article-title":"Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults","volume":"394","author":"Huang","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"(2026, July 05). Vaccines and Related Biological Products Advisory Committee (VRBPAC), Available online: https:\/\/www.fda.gov\/media\/193130\/download."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: Interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1093\/infdis\/jiae329","article-title":"Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1\/2 Randomized Trial","volume":"231","author":"Ananworanich","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_13","unstructured":"Clinicaltrials.gov (2026, July 04). A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults. ID: NCT04956575, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04956575."},{"key":"ref_14","unstructured":"Clinicaltrials.gov (2026, July 04). Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults. ID: NCT05868382, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05868382."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-026-01370-7","article-title":"An mRNA influenza vaccine induces immunity comparable to an adjuvanted vaccine in a randomized trial","volume":"11","author":"Henry","year":"2026","journal-title":"npj Vaccines"},{"key":"ref_16","unstructured":"Clinicaltrials.gov (2026, July 07). A Study of Modified mRNA Vaccines in Healthy Adults. ID: NCT05397223, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05397223."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fierro, C., Sanchez-Crespo, N., Makrinos, D., Zhang, W., Sun, Y., Rohilla, P., Girard, B., Adeniji, A., DiPiazza, A., and Paris, R. (2025). Shared clinical and immunologic features of mRNA vaccines: Preliminary results from a comparative clinical study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1501275"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41541-025-01340-5","article-title":"mRNA-1010 influenza vaccine elicits distinct and enhanced humoral immunity compared to adjuvanted inactivated vaccines","volume":"11","author":"Kaplonek","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41590-026-02569-5","article-title":"mRNA-based influenza vaccine expands the B cell response breadth in humans","volume":"27","author":"Matz","year":"2026","journal-title":"Nat. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"ref_21","unstructured":"Clinicaltrials.gov (2026, July 07). A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults. ID: NCT05606965, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05606965."},{"key":"ref_22","unstructured":"Clinicaltrials.gov (2026, July 07). A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults. ID: NCT05415462, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05415462."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2484088","DOI":"10.1080\/21645515.2025.2484088","article-title":"An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers","volume":"21","author":"Kandinov","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_24","unstructured":"Clinicaltrials.gov (2026, July 07). A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older. ID: NCT05566639, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05566639."},{"key":"ref_25","unstructured":"Clinicaltrials.gov (2026, July 07). Study of mRNA-1010 Seasonal Influenza Vaccine in Adults (IGNITE P303). ID: NCT05827978, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05827978."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"126847","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"key":"ref_27","unstructured":"Clinicaltrials.gov (2026, July 07). A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults \u226550 Years of Age. ID: NCT06602024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06602024."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virs.2026.02.005","article-title":"The role of T cells in influenza infection and vaccination","volume":"41","author":"Li","year":"2026","journal-title":"Virol. Sin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","article-title":"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults","volume":"40","author":"Fraiman","year":"2022","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.vaccine.2023.02.067","article-title":"Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance","volume":"41","author":"Maltezou","year":"2023","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127338","DOI":"10.1016\/j.vaccine.2025.127338","article-title":"RSV vaccines and Guillain-Barr\u00e9 syndrome: Insights into an emerging concern","volume":"61","author":"Anastassopoulou","year":"2025","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/14760584.2022.2100765","article-title":"Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States","volume":"21","author":"Hatziantoniou","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1001\/jama.2025.5646","article-title":"Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults \u226550 Years: A Randomized Clinical Trial","volume":"333","author":"Spergel","year":"2025","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41591-025-03591-0","article-title":"mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: A phase 1\/2 trial","volume":"31","author":"Spergel","year":"2025","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2589644","DOI":"10.1080\/21645515.2025.2589644","article-title":"Phase 1\/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults","volume":"22","author":"Spergel","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2675021","DOI":"10.1080\/21645515.2026.2675021","article-title":"Safety and durability of influenza and SARS-CoV-2 antibody responses through 6 months after a single dose of mRNA-1083, a multicomponent influenza and COVID-19 vaccine, in adults \u226550 years","volume":"22","author":"Kostanyan","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"126463","DOI":"10.1016\/j.vaccine.2024.126463","article-title":"SARS-CoV-2 spike-based virus-like particles incorporate influenza H1\/N1 antigens and induce dual immunity in mice","volume":"42","author":"Stuible","year":"2024","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41541-025-01302-x","article-title":"Establishing long-lasting vaccine immunity: Insights from mRNA and adjuvanted protein platforms","volume":"10","author":"Hasegawa","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s43556-025-00301-7","article-title":"Mucosal immunity and vaccination strategies: Current insights and future perspectives","volume":"6","author":"Zhang","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bullard, B.L., and Weaver, E.A. (2021). Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9030257"},{"key":"ref_41","unstructured":"Clinicaltrials.gov (2026, July 06). Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults. ID: NCT06744205, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06744205."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41541-025-01280-0","article-title":"Advances and prospects of respiratory mucosal vaccines: Mechanisms, technologies, and clinical applications","volume":"10","author":"Li","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jin, R., Wang, B.-Z., and Zhu, W. (2026). Engineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery. Vaccines, 14.","DOI":"10.3390\/vaccines14070596"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1038\/s41591-025-03917-y","article-title":"Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41541-025-01292-w","article-title":"Reproducible and later vaccine strain selection can improve vaccine match to A\/H3N2 seasonal influenza viruses","volume":"10","author":"Lempers","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40259-026-00791-z","article-title":"mRNA Vaccines for Influenza: Hope for a Universal Vaccine?","volume":"40","author":"Omotara","year":"2026","journal-title":"BioDrugs"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Paczkowska, A., Hoffmann, K., Andrzejczak, A., Pucek, W.F., Kopciuch, D., Bryl, W., Nowakowska, E., and Kus, K. (2025). The Application of mRNA Technology for Vaccine Production\u2014Current State of Knowledge. Vaccines, 13.","DOI":"10.3390\/vaccines13040389"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the Cold Reality of mRNA Vaccine Stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/01410768211053006","article-title":"The costs of coronavirus vaccines and their pricing","volume":"114","author":"Light","year":"2021","journal-title":"J. R Soc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"126839","DOI":"10.1016\/j.vaccine.2025.126839","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2023","volume":"51","author":"Taaffe","year":"2025","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lopes de Abreu, A.d.J., Mpande, C.A.M., Song, Y., Nicholson, M.W., Nannei, C., and Friede, M. (2026). Unpacking the mRNA Supply Chain: Challenges and Opportunities for Global Health. Vaccines, 14.","DOI":"10.3390\/vaccines14040324"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e75716","DOI":"10.1002\/adfm.75716","article-title":"Exploring an Alternative to mRNA Vaccine Cold Chain Storage: mRNA-Lipid Nanoparticle Stability When Dried in a Polymer Matrix","volume":"36","author":"Dyett","year":"2026","journal-title":"Adv. Funct. Mater."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s15010-025-02657-y","article-title":"Antiviral strategies against H5N1: Current options and emerging therapeutics","volume":"54","author":"Anastassopoulou","year":"2025","journal-title":"Infection"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"107784","DOI":"10.1016\/j.ijantimicag.2026.107784","article-title":"Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus","volume":"67","author":"Panagiotopoulos","year":"2026","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaf648","article-title":"Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs","volume":"82","author":"Panagiotopoulos","year":"2026","journal-title":"Clin. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:29:32Z","timestamp":1787041772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080709"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080709","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}